Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510069 | 0.87 | ALDH1A1 (0.50) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL18510056 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1TDP1L3MBTL1MEN1 | |
| SCHEMBL27908539 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL28521012 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL5809070 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL27749375 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL30111762 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL10949172 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL29198459 | 0.80 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL20589964 | 0.79 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844081-B2 | Protected organoboronic acids with tunable reactivity, and methods of use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844081-B2 | Protected organoboronic acids with tunable reactivity, and methods of use thereof | CYP2B6, HMBS, DDT | CETP 1614/4885ALDH1A1 1138/4885CYP3A4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.